



P.O. Box 14186  
55 T.W. Alexander Drive  
Research Triangle Park, NC 27709  
tel 919.485.8350  
fax 919.485.8352

To: 340B Covered Entity

From: Kevin Gray, Senior Vice President, Strategic Operations, United Therapeutics Corporation

Date: July 23, 2021

Subject: United Therapeutics Corporation 340B Contract Pharmacy Policy Phase 2 Effective Date Delayed from September 1, 2021 to December 1, 2021

Dear 340B Covered Entity:

We are writing to inform you that the effective date for phase 2 of United Therapeutics Corporation's 340B contract pharmacy policy is being delayed from September 1, 2021 to December 1, 2021. United Therapeutics Corporation previously delayed the phase 2 effective date from May 13, 2021 to September 1, 2021. Phase 1 of the policy has been in effect since November 20, 2020. Both phases of the 340B contract pharmacy policy are described below.

Phase 1—Orders placed on or after November 20, 2020:

- United Therapeutics Corporation will accept 340B contract pharmacy orders placed on or after November 20, 2020 only if the contract pharmacy was utilized by the covered entity for a valid 340B purchase of a United Therapeutics Corporation covered outpatient drug during the first three full quarters of the 2020 calendar year (i.e., January 1 through September 30, 2020).
- United Therapeutics Corporation will deny any 340B contract pharmacy orders where the contract pharmacy does not meet this requirement.
- To identify your contract pharmacies that are eligible under this policy, please visit [UTAssist.com](http://UTAssist.com), select "Our Services" followed by "Product Distribution"
- If a covered entity does not have its own on-site pharmacy and this policy results in the covered entity not having a contract pharmacy, United Therapeutics Corporation will provide the covered entity the opportunity to designate a single contract pharmacy for which United Therapeutics Corporation will accept 340B orders. To apply for this exception, please contact United Therapeutics Corporation at [340b@unither.com](mailto:340b@unither.com).

Phase 2—Orders placed on or after December 1, 2021 (previously September 1, 2021):

- United Therapeutics Corporation will accept 340B contract pharmacy orders placed on or after December 1, 2021 only if the covered entity also has agreed to provide to United Therapeutics Corporation, and is providing on an ongoing basis, claims data associated with all 340B contract pharmacy orders of United Therapeutics Corporation's covered outpatient drugs placed after December 1, 2021 via a platform hosted by a third party with appropriate security and patient privacy safeguards.
- For additional information regarding the platform and the data submission process, refer to the letter United Therapeutics sent to your organization on April 12, 2021.

This policy applies to all of United Therapeutics Corporation's covered outpatient drugs, except for ADCIRCA (tadalafil). United Therapeutics Corporation may revise this policy at its sole discretion at any time and without prior notice.

For questions regarding this policy, please contact United Therapeutics Corporation at [340b@unither.com](mailto:340b@unither.com).